Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr, Schellhammer PF.

J Urol. 2007 Dec;178(6):2314-30. Review. No abstract available.

PMID:
17993339
2.

Bladder and upper tract urothelial cancer.

Konety BR, Joyce GF, Wise M.

J Urol. 2007 May;177(5):1636-45.

PMID:
17437776
3.

Variations in prostate cancer patterns of care: is it the quality of care or the quality of the data?

Penson DF.

J Clin Oncol. 2005 Nov 1;23(31):7783-4. Epub 2005 Oct 11. No abstract available.

PMID:
16219931
4.

Geographic and socioeconomic variation in the treatment of prostate cancer.

Krupski TL, Kwan L, Afifi AA, Litwin MS.

J Clin Oncol. 2005 Nov 1;23(31):7881-8. Epub 2005 Oct 3.

PMID:
16204005
5.

Explaining black-white differences in receipt of recommended colon cancer treatment.

Baldwin LM, Dobie SA, Billingsley K, Cai Y, Wright GE, Dominitz JA, Barlow W, Warren JL, Taplin SH.

J Natl Cancer Inst. 2005 Aug 17;97(16):1211-20.

7.
8.

Bladder carcinoma in situ in 2003: state of the art.

Witjes JA.

Eur Urol. 2004 Feb;45(2):142-6. Review.

PMID:
14733997
9.
10.

Race, socioeconomic status, and breast cancer treatment and survival.

Bradley CJ, Given CW, Roberts C.

J Natl Cancer Inst. 2002 Apr 3;94(7):490-6.

PMID:
11929949
11.

Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer.

Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF.

J Clin Oncol. 2002 Mar 1;20(5):1192-202.

PMID:
11870160
12.

Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.

Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA.

J Natl Cancer Inst. 2001 Dec 19;93(24):1864-71.

PMID:
11752011
13.

Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer.

Hodgson DC, Fuchs CS, Ayanian JZ.

J Natl Cancer Inst. 2001 Apr 4;93(7):501-15. Review.

PMID:
11287444
14.

Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.

Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodríguez J.

J Urol. 2000 Sep;164(3 Pt 1):680-4.

PMID:
10954628
15.
16.

Racial differences in the treatment of early-stage lung cancer.

Bach PB, Cramer LD, Warren JL, Begg CB.

N Engl J Med. 1999 Oct 14;341(16):1198-205.

17.

NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network.

Scher H, Bahnson R, Cohen S, Eisenberger M, Herr H, Kozlowski J, Lange P, Montie J, Pollack A, Raghaven D, Richie J, Shipley W.

Oncology (Williston Park). 1998 Jul;12(7A):225-71.

PMID:
9699218
18.

Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states.

Greenberg ER, Chute CG, Stukel T, Baron JA, Freeman DH, Yates J, Korson R.

N Engl J Med. 1988 Mar 10;318(10):612-7.

PMID:
2830514
19.

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Morales A, Eidinger D, Bruce AW.

J Urol. 1976 Aug;116(2):180-3.

PMID:
820877

Supplemental Content

Support Center